Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golytely vs SUPREP for Bowel Prep in Diabetic Patients
NCT07351019Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Countries
- 1
- Sponsor
- Eisenhower Army Medical Center
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 4, randomised, single-blind trial of sodium sulfate + potassium sulfate + magnesium sulfate (2 arms), sponsored by Eisenhower Army Medical Center. Primary endpoints: Boston Bowel Prep Score and Mayo Bowel Prep Tolerability Score. Started Jan 2026; status: completed.
02
Design
2 arms- Study design
- RandomizedSingle-blind
Golytely Arm
Diabetic patients undergoing bowel prep for screening colonoscopy using Golytely
SUPREP Arm
Diabetic patients undergoing bowel prep for screening colonoscopy using SUPREP
03
Who it enrols
Adult diabetic patients at average screening risk for colon cancer, excluding those with significant systemic diseases, prior colorectal surgery, history of colorectal cancer, IBD, or significant laboratory abnormalities.
04
Endpoints
Primary
Boston Bowel Prep Score
Mayo Bowel Prep Tolerability Score
Beyond the preview
Go deeper on NCT07351019.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07351019.